The system is intended for multiple-patient use in professional healthcare settings as an aid in monitoring the effectiveness of diabetes management programmes and assessing patients at risk of ketosis or diabetic ketoacidosis (DKA).

Diabetic patients with elevated β-HB levels are at increased risk of developing DKA. During metabolic decompensation, β-HB becomes the predominant ketone body, accounting for approximately 78% of circulating ketones. As ketosis develops, the body breaks down stored fats due to insufficient glucose supply, producing β-HB which is subsequently converted into acetoacetate and acetone. Because β-HB reflects changes in a patient’s metabolic condition both before and after treatment, it is considered a more clinically appropriate indicator than traditional nitroprusside urine tests, which do not directly measure β-HB.

The STAT-Site® WB uses two dedicated test strips to deliver rapid results – β-ketone results in just ten seconds and glucose results in five seconds. This enables clear and comprehensive assessment of diabetes patients showing early signs of ketosis or DKA, supporting prompt treatment decisions and ongoing patient monitoring.

Please note: Not all products are available in all countries. Please check with EKF for availability.